MSF claims GSK's intervention reveals ACTA as a front to push for stronger IP rights
This article was originally published in Scrip
The risks inherent in individual pharmaceutical companies raising their heads above the political parapet are illustrated by the response to GlaxoSmithKline's position paper on the Anti-Counterfeiting Trade Agreement (ACTA) from the humanitarian body Médecins Sans Frontières. GSK called for broad adoption of ACTA, a move that MSF feels reveals that ACTA is really about imposing on developing nations intellectual property rules that go beyond those established by the TRIPS agreement of World Trade Organisation.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.